Parecoxib - CAS 198470-84-7
Catalog number: 198470-84-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C19H18N2O4S
Molecular Weight:
370.42
COA:
Inquire
Targets:
Cox-2 | COX
Description:
The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue. Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days. The selective COX-2 inhibitor parecoxib was delivered 20 min before or 20 min after the incision by intraperitoneal injection. Pretreatment with parecoxib markedly attenuated the pain hypersensitivity induced by incision.
Purity:
>98%
Synonyms:
SC 69124; SC69124; SC-69124; Valus-P; Vorth-P
MSDS:
Inquire
InChIKey:
TZRHLKRLEZJVIJ-UHFFFAOYSA-N
InChI:
InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
Canonical SMILES:
CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C
1.Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study.
Zhou ZG1, Chen JB1, Qiu HB1, Wang RJ2, Chen JC1, Xu L1, Chen MS1, Zhang YJ1. Oncotarget. 2016 Apr 2. doi: 10.18632/oncotarget.8560. [Epub ahead of print]
Transarterial chemoembolization(TACE) is the palliative treatment of choice for patients with unresectable hepatocellular carcinoma (HCC). The 242 patients prospectively enrolled in this study were diagnosed with HCC and received TACE at Sun Yat-Sen University Cancer Center between October 2014 and March 2015. Patients were divided into study and control groups based on whether parecoxib sodium was administered postoperatively. Postoperative pain, body temperature, vomiting, changes in liver function, physical activity level, length of hospital stay, and tumor control were evaluated. Compared to the control group after propensity score matching, the study group presented less severe postoperative fever. The daily maximum temperatures in the study and control groups were 37.39 vs. 37.82°Con postoperative day 1 (P < 0.001), 37.10 vs. 37.51°C on day 2 (P < 0.001), and 36.90 vs.37.41°C on day 3 (P < 0.001). The study group also exhibited greater physical activity (P < 0.
2.Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial.
Lv N1, Kong Y2, Mu L1, Pan T1, Xie Q1, Zhao M3. Eur Radiol. 2016 Jan 22. [Epub ahead of print]
OBJECTIVES: Pain is one of the most common side effects of transcatheter arterial chemoembolization (TACE) treatment. This study aimed to assess the analgesic effect of parecoxib sodium for postoperative pain control in patients with inoperable hepatocellular carcinoma (HCC) undergoing TACE.
3.Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration.
Liu M1, Yu Q2, Li P1, Zhu M1, Fang M1, Sun B1, Sun M1, Sun Y1, Zhang P2, He Z1, Sun J1, Wang Y1, Liu X3. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Apr 6;1022:220-229. doi: 10.1016/j.jchromb.2016.04.009. [Epub ahead of print]
In this study, we developed and validated a new, rapid, specific and sensitive ultra-performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) method to simultaneously determine parecoxib sodium (PX) and its active metabolite, valdecoxib (VX), in rat plasma. Plasma samples were prepared by plasma protein precipitation combined with a liquid-liquid extraction method. The separation was carried out on a Kinetex C18 column (2.1mm×50mm, 2.6μm) with a gradient elution using methanol (A) and a 2mM ammonium acetate aqueous solution (B). The analysis was performed in less than 3min with a flow rate of 0.2mL/min. Ketoprofen was used as an internal standard (IS). Mass spectrometric detection was conducted with a triple quadrupole detector equipped with electrospray ionization in the negative ion mode (ESI-) using multiple reaction monitoring (MRM). The calibration curves were linear over the concentration ranges of 5-4000ng/mL for PX and 5-2000ng/mL for VX with all correlation coefficients greater than 0.
4.Parecoxib sodium reduces the need for opioids after tonsillectomy in children: a double-blind placebo-controlled randomized clinical trial.
Li X1, Zhou M2, Xia Q3, Li J3. Can J Anaesth. 2016 Mar;63(3):268-274. Epub 2015 Dec 18.
OBJECTIVE: Postoperative pain is a common phenomenon after pediatric tonsillectomy. This prospective randomized double-blind placebo-controlled clinical trial was performed to evaluate the analgesic efficacy of intravenous parecoxib sodium in children undergoing tonsillectomy.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cox-2 Products


CAS 480-40-0 Chrysin

Chrysin
(CAS: 480-40-0)

Chrysin is a flavonoid with anti-inflammatory, antioxidant and antitumor effects. Chrysin is a central benzodiazepine receptor ligand that has potential anxioly...

CAS 31842-01-0 Indoprofen

Indoprofen
(CAS: 31842-01-0)

Indoprofen, a non-steroidal anti-inflammatory drug, is a cyclooxygenase inhibitor and used for the treatment of pain and inflammation and spinal muscular atroph...

CAS 74103-07-4 Ketorolac

Ketorolac
(CAS: 74103-07-4)

A non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively

CAS 301692-76-2 Polmacoxib

Polmacoxib
(CAS: 301692-76-2)

Polmacoxib is a first-in-class NSAID drug candidate that acts as a dual inhibitor of COX-2 and carbonic anhydrase (CA). It exhibits superior safety for cardiova...

CAS 2438-72-4 Bufexamac

Bufexamac
(CAS: 2438-72-4)

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Comm...

CAS 162054-19-5 SC-58125

SC-58125
(CAS: 162054-19-5)

A selective COX-2 inhibitor

CAS 116686-15-8 FK 3311

FK 3311
(CAS: 116686-15-8)

A selective COX-2 inhibitor

N-acetyl-2-carboxy Benzenesulfonamide
(CAS: 849067-18-1)

A COX-1/COX-2 inhibitor

Chemical Structure

CAS 198470-84-7 Parecoxib

Quick Inquiry

Verification code

Featured Items